Avastin nabs second-in-a-row priority review, this time in ovarian cancer

Last week, it was priority review for cervical cancer. This week, it's the fast track for difficult-to-treat ovarian cancer. That's the record for Roche's ($RHHBY) Avastin, which is now up for quick FDA approval of two new indications. Report